American Society of Clinical Oncology

SHERPA: White

People

  1. Motzer
    Motzer
  2. Scher
    Scher
  3. O'Reilly
    O'Reilly
  4. Saltz
    Saltz
  5. Bajorin
    Bajorin
  6. Kris
    Kris
  7. Hudis
    Hudis
  8. Morris
    Morris
  9. Rosenberg
    Rosenberg
  10. Robson
    Robson

Groups

  1. Department of Medicine (6336)
  2. Solid Tumor Oncology Division (5477)
  3. Survivorship Research (1978)
  4. Genitourinary Oncology Service (1752)
  5. Surgery (1623)
  6. Epidemiology and Biostatistics (1468)
  7. GSK Faculty (1374)
  8. Population Sciences Research Program (1357)
  9. Gastrointestinal Oncology Service (1342)
  10. Hematologic Malignancies, Division of (1269)
Search Within
Formats
  1. Meeting Abstract (6252)
  2. Journal Article (2560)
  3. Editorial (73)
  4. Review (65)
  5. Guidelines (54)
  6. Correspondence (48)
  7. Miscellaneous (4)
  8. Conference Paper (3)
Groups
  1. Department of Medicine (6336)
  2. Solid Tumor Oncology Division (5477)
  3. Survivorship Research (1978)
  4. Genitourinary Oncology Service (1752)
  5. Surgery (1623)
  6. Epidemiology and Biostatistics (1468)

More Groups

People
  1. Robert Motzer (447)
  2. Howard Scher (334)
  3. Eileen O'Reilly (303)
  4. Leonard Saltz (283)
  5. Dean Bajorin (278)
  6. Mark Kris (252)

More People

Years
  1. 2025 (167)
  2. 2024 (554)
  3. 2023 (580)
  4. 2022 (554)
  5. 2021 (504)
  6. 2020 (539)

More Years

Publications
  1. Journal of Clinical Oncology (8596)
  2. JCO Precision Oncology (165)
  3. Journal of Oncology Practice (124)
  4. American Society of Clinical Oncology Educational Book (112)
  5. JCO Clinical Cancer Informatics (53)
  6. JCO Oncology Practice (4)

More Publications

Results (9059)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Evolving metastatic renal cell carcinoma (mRCC) treatment landscape in the post vascular endothelial growth factor (VEGF) and immune checkpoint inhibitor (IO) setting
    Meeting Abstract

    Shah, N. J.; Bhattacharya, R.; Ning, N.; Shinde, R.; Schmier, J.; Tan, M. L. D.; Lemasters, T.; Sundaram, M.; Perini, R. F.; Motzer, R. J.
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Post radical prostatectomy (RP) PSA outcomes following 6 versus 18 months of perioperative androgen receptor signaling inhibitors (ARSI) in men with localized high-risk prostate cancer: Results of Part 2 of a randomized phase 2 trial
    Meeting Abstract

    McKay, R. R.; Xie, W.; Yang, X.; Acosta, A.; Rathkopf, D. E.; Laudone, V. P.; Bubley, G.; Einstein, D. J.; Chang, P. T.; Wagner, A.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Baseline disease characteristics of participants enrolled on ENZARAD (ANZUP1303) and DASL-HiCaP (ANZUP1801) trials of highly effective androgen receptor antagonists in high-risk localized or locally advanced prostate cancer (PCa)
    Meeting Abstract

    Niazi, T.; Nguyen, P. L.; Williams, S.; Stockler, M. R.; Martin, A. J.; Horvath, L.; Thomas, H.; Sinikovic Zebic, D.; Roncolato, F.; Lim, T.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Nivolumab plus cabozantinib (N plus C) vs sunitinib (S) for previously untreated advanced renal cell carcinoma (aRCC): Results from 55-month follow-up of the CheckMate 9ER trial
    Meeting Abstract

    Bourlon, M. T.; Escudier, B.; Burotto, M.; Powles, T.; Apolo, A. B.; Shah, A. Y.; Porta, C.; Suárez, C.; Barrios, C. H.; Richardet, M.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Nivolumab plus ipilimumab (NIVO + IPI) vs sunitinib (SUN) for first-line treatment of advanced renal cell carcinoma (aRCC): Long-term follow-up data from the phase 3 CheckMate 214 trial
    Meeting Abstract

    Escudier, B.; McDermott, D. F.; Burotto, M.; Choueiri, T. K.; Hammers, H. J.; Plimack, E. R.; Porta, C.; George, S.; Powles, T.; Donskov, F.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Patient-reported health-related quality of life (HRQoL) in the randomized FORMULA-509 trial of salvage radiotherapy and 6 months of GnRH agonist with either bicalutamide or abiraterone acetate plus prednisone (AAP) and apalutamide (Apa) after radical prostatectomy (RP)
    Meeting Abstract

    Hoffman, K. E.; Nguyen, P. L.; Rathkopf, D. E.; Zurita, A. J.; Spratt, D. E.; Dess, R. T.; Liauw, S. L.; Szmulewitz, R. Z.; Einstein, D. J.; Bubley, G.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Randomized trial of transperineal versus transrectal prostate biopsy to prevent infection complications
    Meeting Abstract

    Hu, J. C.; Vickers, A.; Allaf, M. E.; Ehdaie, B.; Cohen, A. J.; Ristau, B. T.; Green, D.; Han, M.; Rezaee, M.; Pavlovich, C. P.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Prostate Cancer Foundation (PCF) screening guidelines for prostate cancer in Black men in the United States
    Meeting Abstract

    Garraway, I.; Carlsson, S. V.; Nyame, Y. A.; Vassey, J.; Chilov, M.; Fleming, M. T.; Frencher, S. K.; George, D. J.; Kibel, A. S.; King, S. A.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • EMBARK post hoc analysis of sexual activity (SA) patient-reported outcome (PRO) measures
    Meeting Abstract

    Freedland, S. J.; Mulhall, J.; Gleave, M.; De Giorgi, U.; Saad, F.; Rannikko, A.; Ivanova, J. I.; Nasr, A.; Reisman, A.; Ganguli, A.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Phase 1/2 trial of oral EPI-7386 (masofaniten) in combination with enzalutamide (Enz) compared to Enz alone in patients with metastatic castration-resistant prostate cancer (mCRPC): Phase 1 (P1) results and phase 2 (P2) design
    Meeting Abstract

    Kyriakopoulos, C.; Chatta, G. S.; Laccetti, A. L.; Iannotti, N.; Sokolova, A.; Hotte, S. J.; Tutrone, R. F.; Markowski, M. C.; Nordquist, L. T.; Pili, R.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save